ABIVAX: Update on shares and voting rights as of December 31, 2024

ABIVAX, the biotechnology company listed on Euronext Paris, has communicated regulatory information concerning the number of its shares and the associated voting rights as of December 31, 2024. In total, 63,347,837 shares make up the share capital of the company, which is equivalent to a capital of 633,655.65 euros.

The total number of voting rights, amounting to 70,991,046, is divided into theoretical and exercisable voting rights. These figures include shares without voting rights, in accordance with current legislation and the recommendations of the Financial Markets Authority. This ensures optimal transparency regarding the participation thresholds in the company.